國立虎尾科技大學 |

Novel Biomarkers in the Continuum of Breast Cancer

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Novel Biomarkers in the Continuum of Breast Cancer/ edited by Vered Stearns.
其他作者:	Stearns, Vered.
面頁冊數:	XIX, 279 p. 34 illus., 4 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-319-22909-6
ISBN:	9783319229096

Novel Biomarkers in the Continuum of Breast Cancer
Novel Biomarkers in the Continuum of Breast Cancer[electronic resource] /edited by Vered Stearns. - 1st ed. 2016. - XIX, 279 p. 34 illus., 4 illus. in color.online resource. - Breast Cancer Research Foundation ;882. - Breast Cancer Research Foundation ;862.

1 Genomic Biomarkers for Cancer Risk -- 2 Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum -- 3 Incorporating Biomarkers in Studies of Chemoprevention -- 4 Breast Molecular Profiling and Radiotherapy Considerations -- 5 Prognostic and Predictive Biomarkers of Endocrine Responsiveness For Estrogen Receptor Positive Breast Cancer -- 6 Biomarkers for predicting response to Anti-HER2 Agents -- 7 Intratumor Heterogeneity in Breast Cancer -- 8 Intratumor Heterogeneity in Breast Cancer -- 9 Pharmacogenetic Predictors of Response -- 10 Metabolomics in Breast Cancer: Current Status and Perspectives -- 11 Circulating Tumor Cells -- 12 Circulating Plasma Tumor DNA.

This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today’s standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment for individual patients.

ISBN: 9783319229096

Standard No.: 10.1007/978-3-319-22909-6doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Novel Biomarkers in the Continuum of Breast Cancer
LDR:03031nam a22004095i 4500 001 972338
003 DE-He213
005 20200630040916.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319229096 $9 978-3-319-22909-6
024 7 $a 10.1007/978-3-319-22909-6 $2 doi
035 $a 978-3-319-22909-6
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Novel Biomarkers in the Continuum of Breast Cancer $h [electronic resource] / $c edited by Vered Stearns.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a XIX, 279 p. 34 illus., 4 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Breast Cancer Research Foundation ; $v 882
505 0 $a 1 Genomic Biomarkers for Cancer Risk -- 2 Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum -- 3 Incorporating Biomarkers in Studies of Chemoprevention -- 4 Breast Molecular Profiling and Radiotherapy Considerations -- 5 Prognostic and Predictive Biomarkers of Endocrine Responsiveness For Estrogen Receptor Positive Breast Cancer -- 6 Biomarkers for predicting response to Anti-HER2 Agents -- 7 Intratumor Heterogeneity in Breast Cancer -- 8 Intratumor Heterogeneity in Breast Cancer -- 9 Pharmacogenetic Predictors of Response -- 10 Metabolomics in Breast Cancer: Current Status and Perspectives -- 11 Circulating Tumor Cells -- 12 Circulating Plasma Tumor DNA.
520 $a This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today’s standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment for individual patients.
650 0 $a Cancer research. $3 1253664
650 0 $a Oncology . $3 1253469
650 0 $a Human genetics. $3 596505
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Oncology. $3 593951
650 2 4 $a Human Genetics. $3 593893
700 1 $a Stearns, Vered. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1106449
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319229089
776 0 8 $i Printed edition: $z 9783319229102
776 0 8 $i Printed edition: $z 9783319794341
830 0 $a Breast Cancer Research Foundation ; $v 862 $3 1255110
856 4 0 $u https://doi.org/10.1007/978-3-319-22909-6
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)